Jack Anders - Revolution Medicines, Chief Officer
| RVMDW Stock | 0.07 0.01 10.88% |
Executive
Jack Anders is Chief Officer of Revolution Medicines, Warrant
| Age | 49 |
| Phone | 650 481 6801 |
| Web | https://www.revmed.com |
Jack Anders Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jack Anders against Revolution Medicines, stock is an integral part of due diligence when investing in Revolution Medicines,. Jack Anders insider activity provides valuable insight into whether Revolution Medicines, is net buyers or sellers over its current business cycle. Note, Revolution Medicines, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Revolution Medicines,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jack Anders over six months ago Acquisition by Jack Anders of 26400 shares of Revolution Medicines subject to Rule 16b-3 |
Revolution Medicines, Management Efficiency
The company has return on total asset (ROA) of (0.1866) % which means that it has lost $0.1866 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2933) %, meaning that it generated substantial loss on money invested by shareholders. Revolution Medicines,'s management efficiency ratios could be used to measure how well Revolution Medicines, manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matt Madrigal | N/A | ||
| Daniel Susik | Ryder System | N/A | |
| Kristina TreaseWhitney | McGrath RentCorp | 55 | |
| Donald Reilly | KVH Industries | 65 | |
| Alexis Gil | Integral Ad Science | 53 | |
| Sabrina Ellis | 51 | ||
| Tara Wescott | McGrath RentCorp | 50 | |
| Francisco Lopez | Ryder System | 50 | |
| Laura Quigley | Integral Ad Science | N/A | |
| Todd Skiles | Ryder System | N/A | |
| Alexis II | Integral Ad Science | 52 | |
| Stuart Porter | McGrath RentCorp | 52 | |
| Jeremy King | 55 | ||
| David CPA | McGrath RentCorp | 60 | |
| Bill Watkins | N/A | ||
| Doniel Sutton | 50 | ||
| Jennifer Baker | KVH Industries | 46 | |
| Jim Egan | Integral Ad Science | N/A | |
| Wanjiku JD | 54 | ||
| Richard Driscoll | KVH Industries | N/A | |
| Matthew Madrigal | N/A | ||
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.19 |
Revolution Medicines, Leadership Team
Elected by the shareholders, the Revolution Medicines,'s board of directors comprises two types of representatives: Revolution Medicines, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revolution. The board's role is to monitor Revolution Medicines,'s management team and ensure that shareholders' interests are well served. Revolution Medicines,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revolution Medicines,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jack Anders, Chief Officer | ||
| Erin Graves, Senior Relations | ||
| Walter Reiher, Chief Officer | ||
| Mark Goldsmith, President CEO | ||
| Path FRCP, President Development | ||
| Margaret JD, Chief Officer | ||
| Michael Fischbach, Academic Board | ||
| Xiaolin Wang, Executive Development | ||
| Kevan Shokat, Academic Board | ||
| Jan Smith, Chief Officer |
Revolution Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revolution Medicines, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.19 | ||||
| Number Of Shares Shorted | 2.25 K | ||||
| Gross Profit | (592.23 M) | ||||
| EBITDA | (689.52 M) | ||||
| Net Income | (600.09 M) | ||||
| Total Debt | 135.84 M | ||||
| Book Value Per Share | 12.19 X | ||||
| Cash Flow From Operations | (557.44 M) | ||||
| Number Of Employees | 534 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Revolution Stock Analysis
When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.